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1 |  INTRODUCTION
Numerous publications, including some of ours, have stated 
that metastases are responsible for 90% of cancer deaths.1-4 
Clinical experience and biological reasoning would suggest 
that this is true. The statement is frequently used to justify a 
reinforced research focus on the biology of metastases. When 
looking into the references for this statement, however, it is 
unclear what data, if any, underlies this assertion. Scientific 
papers in which the statement appears refer to other papers 
that state the same thing. Those papers refer to yet others 
and after a few such rounds, the statement merely claims that 
most cancer deaths are caused by metastatic disease, with-
out any references.5-8 In our literature search, many of these 
reference pathways converge on a commentary by Sporn in 
The Lancet in 19965 that actually does not touch upon the 
subject of what proportion of cancer deaths are caused by 
metastatic disease at all. Immense progress has been made 
in diagnosis and treatment of cancer since 1996, so even 
assuming that there was at some time point data supporting 
this statement, we need not conclude that this still holds true 
today. For example, childhood leukemia cure rates have in-
creased substantially the last decades, thereby lowering the 
number of total cancer deaths registered as nonmetastatic dis-
ease. In breast cancer, improved diagnosis and treatment has 
led to a decline in total numbers of deaths as well as deaths 
from metastatic disease in relation to incidence, as incidence 
is increasing.9 Thus, it is not clear how improved diagnosis 
and treatment will affect the fraction of cancer deaths accom-
panied by metastasis (ie, #cancer deaths with metastasis/#-
cancer deaths). Improved care will presumably decrease both 
cancer deaths and cancer deaths from metastasis, but the ef-
fect on the fraction of deaths from metastasis is not obvious.
When considering deaths from cancer without metastatic 
disease as an underlying cause, a few different scenarios 
come to mind. First, we have cases where local tumors affect 
vital organs, such as airways, brain, heart, and liver. Second, 
systemic cancer treatment and its side effects can be fatal by 
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Abstract
Numerous publications have stated that metastases are responsible for 90% of cancer 
deaths, but data underlying this assertion has been lacking. Our objective was to 
determine what proportions of cancer deaths are caused by metastases. Population‐
based data from the Cancer Registry of Norway for the years 2005‐2015 was ana-
lyzed. We compared all deaths in the Norwegian population where a cancer diagnosis 
was registered as cause of death. Deaths caused by cancer, with and without metas-
tases, were analyzed, by sex and tumor group. For solid tumors, 66.7% of cancer 
deaths were registered with metastases as a contributing cause. Proportions varied 
substantially between tumor groups. Our data support the idea that the majority of 
deaths from solid tumors are caused by metastases. Thus, a better understanding of 
the biology of metastases and identification of druggable targets involved in growth 
at the metastatic site is a promising strategy to reduce cancer mortality.
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multiple organ failure, bleeding due to thrombocytopenia, in-
fections, interstitial pneumonitis, and tumor lysis syndrome 
to name a few. Third, surgical treatment and its potential 
complications can also have a fatal outcome. Fourth, tragi-
cally, some patients commit suicide after a cancer diagnosis, 
however, a recent publication on the SEER database demon-
strated this to be more frequent in patients with metastatic 
disease.10
2 |  METHODS
As Norway has a tradition of robust and reliable registries, 
we set out to find the data to support or refute this truism. 
Reporting to the Cancer Registry of Norway and the Cause 
of Death Registry of Norway is mandatory for all physi-
cians, and the latest published evaluation showed a 98.8% 
completeness of data.11 The registries record whether or not 
the cancer patient had been diagnosed with metastases, ei-
ther before death or at autopsy if this was performed. We 
assumed that cancer death in a patient with metastatic dis-
ease would be caused by the metastases and not by the pri-
mary tumor, even in the rare occasions when the primary 
tumor was still intact. The latest available complete data 
are from 2015. In this year, a total of 10 944 cancer deaths 
were registered. Data are also available for primary site and 
sex. Site stratification is crucial, as some cancer forms are 
highly aggressive and associated with short survival even 
though they rarely metastasize, the best example probably 
being glioblastoma. We calculated the proportions of deaths 
from metastatic and nonmetastatic cancers in total and after 
excluding deaths from malignancies of lymphoid or hemat-
opoietic origin (n = 1052), leaving 9892 cancer deaths in 
patients with solid tumors.
3 |  RESULTS
When looking at all cancer deaths per year from 2005 to 
2016, there is surprisingly little change, from 10  575 in 
2005 to 10 814 in 2016. The number of cancer deaths reg-
istered with metastasis as contributing cause of death on 
the other hand demonstrates a tripling, from 1953 (18.5%) 
in 2005 to 5575 (55.5%) in 2016. When looking into the 
details of the latest year (2015) with complete data on dif-
ferent tumor groups, our suspicion of substantial variation 
between tumor groups was confirmed. The proportions 
of all cancer deaths that were registered with metastasis 
ranged from 100% (testicular cancer, nose sinus) to 9.3% 
in central nervous system cancers (Table 1). For prostate 
cancer, the rate of cancer deaths registered with metastases 
as contributing cause was only 50.5%, a proportion that 
clinical experience would suggest to be almost all. Breast 
cancer incidence has been rising over the last decade, 
while deaths from breast cancer are declining. The propor-
tion of deaths caused by metastatic disease, however, is 
remarkably stable (Table 2). For all solid tumors, the rate 
was 66.7%.
 
All cancer deaths Cancer deaths with metastases
Male Female Male (%) Female (%) Total (%)
All cancer 5810 4936 3390 (58.3) 3118 (63.2) 6508 (60.1)
Solid tumorsa 5229 4493 3374 (64.5) 3109 (69.2) 6483 (66.7)
Colon 536 600 445 (83.0) 466 (77.7) 911 (80.2)
Lung/trachea 1169 973 918 (78.5) 747 (76.8) 1665 (77.7)
Breast 6 583 5 (83.3) 440 (75.5) 445 (75.6)
Ovary 0 282 0 255 (90.4) 255 (90.4)
Prostate 1034 0 519 (50.2) 0 519 (50.2)
CNS 199 165 25 (12.6) 9 (5.5) 34 (9.3)
aExcluding lymphomas and hematologic malignancies 
T A B L E  1  Cancer deaths in Norway 
2015








2007 2729 697 529 (75.9) 25.5% 19.4%
2010 2849 663 509 (76.8) 23.3% 17.9%
2015 3422 589 445 (75.6) 17.2% 13.0%
T A B L E  2  Breast cancer in Norway
5576 |   DILLEKÅS Et aL
4 |  DISCUSSION
Having read the statement that metastases are responsi-
ble for 90% of deaths from cancer in a number of papers, 
that did not seem to have supporting data, neither in them-
selves nor in references, we sought to evaluate this truism. 
The reasons it has become such a widely accepted notion 
are worth some consideration. First, experience from the 
clinic is consistent with the proportion being in this range. 
Second, biological reasoning would also suggest that very 
few localized tumors are capable of killing the patient. 
Third, since it has been written in seminal papers by some 
of the most prominent cancer scientists, it has been given 
substantial weight. When more and more papers have writ-
ten it, the “evidence” of it being true seems to accumulate, 
even in the absence of supporting data. In this nationwide, 
population‐based registry study, we found that 66.7% of 
cancer deaths in solid tumors were caused by metastases. 
The proportion of deaths attributed to metastatic disease 
has been increasing dramatically over the last decade. 
It seems unlikely that this reflects clinical reality and is 
more likely due to increased focus on correct registration 
in death certificates. Based on clinical experience, these 
numbers still seem far too low, and interviews with staff 
from the registry confirmed that whereas synchronous me-
tastases (ie, metastases diagnosed at the same time as the 
primary tumor) is well reported, metachronous metastases 
(metastases discovered at some later time point) are under-
reported. As described above, registration rates seem to be 
improving, but still, based on Norwegian registry data, we 
unfortunately cannot determine the precise proportion of 
cancer deaths caused by metastatic disease. The improv-
ing registration rates over the past decade, however, give 
reason to hope that we will be able to answer this question 
with robust, reliable data in the future. Nevertheless, our 
data support the idea that the majority of deaths (at least 
2/3) from solid tumors are caused by metastases. Thus, 
a better understanding of the biology of metastases and 
identification of druggable targets involved in growth at 
the metastatic site is a promising strategy to reduce cancer 
mortality.
5 |  DISCLAIMER
This work uses data from the Norwegian Cancer Registry. 
Interpretation and reporting of this data is the sole respon-
sibility of the authors, and has not been subject of approval 
from the Norwegian Cancer Registry.
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